SCHEMBL12875498

SCHEMBL12875498

Cc1c(C(=O)O)cnn1-c1nc(-c2ccc(Cl)cc2)cs1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.71
NPC1 O15118 6/20 0.71
MEN1 O00255 6/20 0.71
KMT2A Q03164 6/20 0.71
KDM4E B2RXH2 7/20 0.56
CRHBP P24387 1/20 0.55
MC4R P32245 1/20 0.55
CRHR2 Q13324 1/20 0.55
ATM Q13315 1/20 0.55
PTGER4 P35408 1/20 0.53
MAPT P10636 6/20 0.53
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
SPR P35270 1/20 0.49
HPGD P15428 4/20 0.48
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
GAA P10253 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255206 0.90 RAB9A (0.58) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL14196468 0.89 RAB9A (0.60) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL12875465 0.89 RAB9A (0.63) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL12875471 0.88 RAB9A (0.72) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL1198595 0.87 MEN1 (0.72) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL4821930 0.86 KDM4E (0.58) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL4823256 0.85 KDM4E (0.65) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL1198727 0.83 MEN1 (1.00) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL4827487 0.83 PTGER4 (0.77) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL12875525 0.82 MEN1 (0.52) RAB9ANPC1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-7358267-B2 Bis-aryl thiazole derivatives AMGEN INC. (US) 2008-04-15 US disclosed
US-7358267-B2 Bis-aryl thiazole derivatives AMGEN INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A RAB9A 2507/4885NPC1 3877/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.